1. Home
  2. SWKH vs NYXH Comparison

SWKH vs NYXH Comparison

Compare SWKH & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SWK Holdings Corporation

SWKH

SWK Holdings Corporation

HOLD

Current Price

$17.04

Market Cap

175.5M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$4.89

Market Cap

188.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWKH
NYXH
Founded
1996
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Diversified Financial Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
175.5M
188.1M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
SWKH
NYXH
Price
$17.04
$4.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$18.00
$12.67
AVG Volume (30 Days)
10.3K
56.1K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
120.89
N/A
EPS
1.85
N/A
Revenue
$40,149,000.00
$6,616,215.00
Revenue This Year
$52.93
$79.25
Revenue Next Year
N/A
$297.08
P/E Ratio
$9.25
N/A
Revenue Growth
62.38
10.96
52 Week Low
$13.17
$4.35
52 Week High
$20.49
$11.87

Technical Indicators

Market Signals
Indicator
SWKH
NYXH
Relative Strength Index (RSI) 58.62 47.14
Support Level $16.69 $4.60
Resistance Level $17.75 $5.01
Average True Range (ATR) 0.31 0.24
MACD 0.02 0.03
Stochastic Oscillator 55.24 71.67

Price Performance

Historical Comparison
SWKH
NYXH

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: